Օֆտան

main_info

  • trade_name:
  • Օֆտան դեքսամեթազոն
  • dosage:
  • 1մգ/մլ5մլ պլաստիկե սրվակ
  • pharmaceutical_form:
  • ակնակաթիլներ
  • prescription_type:
  • Դեղատոմսով
  • medicine_domain:
  • Human
  • medicine_type:
  • Allopathic

documents

localization

  • country:
  • Օֆտան դեքսամեթազոն
    አርሜኒያ
  • language:
  • አማርኛ

other_info

status

  • source:
  • Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում - Armenia
  • last_update:
  • 31-05-2018

19-12-2018

Safety and efficacy of vitamin B2 (riboflavin 5′‐phosphate ester monosodium salt) for all animal species when used in water for drinking

Safety and efficacy of vitamin B2 (riboflavin 5′‐phosphate ester monosodium salt) for all animal species when used in water for drinking

Published on: Tue, 18 Dec 2018 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on vitamin B2 in the form of riboflavin 5′‐phosphate ester monosodium salt as an additive for all animal species for use in water for drinking. The additive under assessment is obtained from ■■■■■ a source of riboflavin produced by Ashbya gossypii. No information was provided on the identity and character...

Europe - EFSA - European Food Safety Authority EFSA Journal

15-3-2019

EU/3/15/1597 (Otsuka Pharmaceutical Netherlands B.V.)

EU/3/15/1597 (Otsuka Pharmaceutical Netherlands B.V.)

EU/3/15/1597 (Active substance: Sodium (2R,3S,5R)-5-(4-amino-2-oxo-1,3,5-triazin-1(2H)-yl)-2-(hydroxymethyl)tetrahydrofuran-3-yl ((2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9(6H)-yl)-3-hydroxytetrahydrofuran-2-yl)methyl phosphate) - Transfer of orphan designation - Commission Decision (2019)2107 of Fri, 15 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004914

Europe -DG Health and Food Safety

20-2-2019


Opinion/decision on a Paediatric investigation plan (PIP): Complex of povidone and iodine,dexamethasone (SHP640), decision type: , therapeutic area: , PIP number: P/0369/2018

Opinion/decision on a Paediatric investigation plan (PIP): Complex of povidone and iodine,dexamethasone (SHP640), decision type: , therapeutic area: , PIP number: P/0369/2018

Opinion/decision on a Paediatric investigation plan (PIP): Complex of povidone and iodine,dexamethasone (SHP640), decision type: , therapeutic area: , PIP number: P/0369/2018

Europe - EMA - European Medicines Agency

18-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Levofloxacin / dexamethasone, decision type: , therapeutic area: , PIP number: P/0277/2018

Opinion/decision on a Paediatric investigation plan (PIP): Levofloxacin / dexamethasone, decision type: , therapeutic area: , PIP number: P/0277/2018

Opinion/decision on a Paediatric investigation plan (PIP): Levofloxacin / dexamethasone, decision type: , therapeutic area: , PIP number: P/0277/2018

Europe - EMA - European Medicines Agency

22-11-2018

Ozurdex (Allergan Pharmaceuticals Ireland)

Ozurdex (Allergan Pharmaceuticals Ireland)

Ozurdex (Active substance: dexamethasone) - PSUSA - Modification - Commission Decision (2018)7886 of Thu, 22 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1140/PSUSA/985/201801

Europe -DG Health and Food Safety

24-9-2018

Neofordex (Laboratoires CTRS)

Neofordex (Laboratoires CTRS)

Neofordex (Active substance: dexamethasone) - Centralised - Yearly update - Commission Decision (2018)6239 of Mon, 24 Sep 2018

Europe -DG Health and Food Safety